News | Artificial Intelligence | December 07, 2021

Study results demonstrate the accuracy of AI-based ultrasound software, enabling a quicker detection of right ventricle dysfunction caused by COVID-19, pulmonary embolism, and more

DiA Imaging Analysis, a leading provider of advanced AI-based software for ultrasound analysis, was featured in a recent study presented by a team of cardiac physicians from Mount Sinai's Icahn School of Medicine at the American Heart Association meeting.

December 7, 2021 — DiA Imaging Analysis, a leading provider of advanced AI-based software for ultrasound analysis, was featured in a recent study presented by a team of cardiac physicians from Mount Sinai's Icahn School of Medicine at the American Heart Association meeting. The breakthrough study demonstrated the accuracy of LVivo RV, the company's AI for right ventricle function analysis, validating its sensitivity and specificity results compared to Cardiac MRI (CMR).

Right Ventricle (RV) size and function are vital indicators of cardiac dysfunction, including pulmonary embolism (PE), pulmonary hypertension, and right heart failure. Amid the COVID-19 pandemic, cardiac ultrasound imaging includes assessment of the RV to detect RV dysfunction, commonly seen in patients with COVID-19. Although common, RV function analysis using an ultrasound device is difficult and often requires additional examination due to the RV's challenging geometry. 

The recent study of 125 patients compared DiA's right heart AI-based software to CMR. Results demonstrated high sensitivity and specificity when compared to CMR, the gold standard of cardiac imaging. The study concluded that DiA's automated AI-based right heart analysis for automated RV function quantification has the potential to accurately and instantly detect evidence of right heart dysfunction at the echo lab and near the bedside.

Dr. Martin Goldman, professor of cardiology at Mount Sinai and a leading author of the study said, "As echo is the first imaging triage modality used for scanning suspected heart issues, this study validated the potential of adding AI as part of our cardiac ultrasound workflow." 

"We are proud to share that leading physicians from the Icahn School of Medicine at Mount Sinai, a globally ranked program, have validated our FDA-approved AI software," said Hila Goldman-Aslan, CEO and co-founder of DiA Imaging Analysis. "The study demonstrated that LVivo RV can provide an automated and accurate solution to the critical analysis of the right ventricle function using ultrasound." 

The study, Validation of Artificial Intelligence for Assessing Right Ventricular Function by Transthoracic Echocardiography, was conducted by Brian Hsia, Ashton Lai, Rajeev Samtani, Solomon Bienstock, Steve Liao, Eric Stern, Gina LaRocca, Javier Sanz, Stamatios Lerakis, Gregg W Stone, Lori Croft, and Martin Goldman, of the Icahn School of Medicine at Mount Sinai, New York, NY. The results were presented to the American Heart Association on November 15, 2021. The study was published in Circulation Magazine, Volume 144, Issue 1.

For more information: www.dia-analysis.com/

Related RSNA2021 content


Related Content

Feature | Breast Imaging

Despite decades of progress in breast imaging, one challenge continues to test even the most skilled radiologists ...

Time October 24, 2025
arrow
News | Contrast Media

Oct. 21, 2025 — Subtle Medical, Inc., a provider of AI-powered medical imaging solutions, has announced positive ...

Time October 21, 2025
arrow
News | Artificial Intelligence

Oct. 20, 2025 — Viz.ai has launched of Viz Assist, a suite of autonomous AI agents that significantly enhance how care ...

Time October 20, 2025
arrow
News | CT Angiography (CTA)

Oct. 9, 2025 — RapidAI recently announced that its Lumina 3D built on the Rapid Enterprise Platform has been named to ...

Time October 16, 2025
arrow
News | Point-of-Care Ultrasound (POCUS)

Oct. 15, 2025 — GE HealthCare has announced the latest advancement in its Venue family of point-of-care ultrasound ...

Time October 16, 2025
arrow
News | RSNA 2025

Oct. 7, 2025 — RSNA Ventures, a mission-aligned subsidiary of Radiological Society of North America (RSNA), has ...

Time October 08, 2025
arrow
News | RSNA 2025

Oct. 7, 2025 – Clairity Inc., a leader in AI-based breast cancer risk prediction, will make five scientific ...

Time October 07, 2025
arrow
News | Magnetic Resonance Imaging (MRI)

Oct. 6, 2025 — Hyperfine, Inc. has launched the Portable Ultra-Low-Field Scientific Exchange (PULSE), a subscription ...

Time October 06, 2025
arrow
News | Mammography

Sept. 26, 2025 — Data from two groundbreaking studies evaluating the performance of Hologic’s artificial intelligence ...

Time October 02, 2025
arrow
News | Computed Tomography (CT)

Sept. 29, 2025 — Many studies have shown the inverse relationship between bone mineral density (BMD) — the gold standard ...

Time September 30, 2025
arrow
Subscribe Now